Abstract
Sickle Cell Disease (SCD) poses a substantial healthcare challenge, particularly due to its prevalence and the high cost of care. Traditional diagnostic methods are cumbersome, require significant time, and depend on centralized laboratories, which hinders timely and efficient patient management.
Researchers at Florida Atlantic University have developed a breakthrough micro impedance device (μZAS) that represents a significant leap in SCD diagnostics. The device enables rapid, accurate measurement of sickle cell properties directly from whole blood. By providing real-time results at the point of care, it greatly simplifies the monitoring and management process for SCD. This not only enhances patient care but also promises to substantially reduce healthcare costs.
FAU seeks to advance this innovation into the marketplace through licensing or development partnerships.
Benefit
Rapid - Delivers quick, accurate readingsCost-Effective - Reduces medical expensesUser-Friendly - Simple operation for patients and providersMarket Application
Medical Diagnostics - Essential tool for hospitals and clinicsRemote Healthcare - Ideal for areas with limited lab accessPatient Monitoring - Continuous management of SCD patients
Brochure
